1 / 28

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial. Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after Rectal Cancer Resection is Strongly Related to the Plane of Surgical Dissection 2006 ASCO abstracts 3511, 3512

brooke-stafford
Download Presentation

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after Rectal Cancer Resection is Strongly Related to the Plane of Surgical Dissection 2006 ASCO abstracts 3511, 3512 Discussant: Al B. Benson III, MD, FACP Northwestern University Feinberg School of Medicine

  2. Advances in Rectal Cancer Staging, Radiation, Surgery • Endorectal Ultrasound (ERUS) • Preoperative Chemoradiation • Sphincter Preservation • Total Mesorectal Excision (TME) • Circumferential Resection Margin (CRM) • Adequate Lymph Node Dissection

  3. Adjuvant radiation therapy Preoperative • Potential downstaging • Improved probability of sphincter-sparing • Decreased operative seeding • Lower chronic toxicity • Potential overtreatment • Increased surgical morbidity Postoperative • Accurate staging and selection of adjuvant therapy • Increased radiation morbidity

  4. Advantages of different preoperative regimens • European approach • Short course – high dose – immediate surgery • No change in path staging • Lower cost • Better compliance • Dose equivalent to 30-33 Gy • Expect 66% reduction in local recurrence • American approach • Prolonged course – high dose – delayed surgery • Better surgical tolerance • More tumor regression • Expect >80% reduction in local recurrence Withers HR and Haustermans K, 2004; Int J Rad Onc Biol Phys 58(2):597-602.

  5. Advances in Rectal Cancer Advances in Rectal Cancer Staging, Radiation, Surgery • Endorectal Ultrasound (ERUS) • Preoperative Chemoradiation • Sphincter Preservation • Total Mesorectal Excision (TME) • Circumferential Resection Margin (CRM) • Adequate Lymph Node Dissection

  6. Clinically operable adenocarcinoma of the rectum <15cm from anal verge; no metastases Randomise POST PRE Pre-operative RT 25Gy / 5F Surgery Pathology Surgery CRM-ve CRM+ve Pathology Post-op CRT 45Gy / 25F + concurrent 5FU No RT Adjuvant chemotherapy given as per local policy Trial Design

  7. MRC CR07 / NCIC C016 • Large Study: 1,350 patients • Completion of a Pre-op vs Post-op Trial • 50% patients: T3 N0 Adjuvant tx: 1,090 patients (81%) CRM: 13%

  8. 100 90 80 70 LR rate (%) 60 50 40 30 20 10 0 5 0 1 2 3 4 Time(Years) LR by treatment (ITT) N Events 3yr LR 5yr LR PRE 674 23 5% 5% POST 676 61 11% 17% HR(95%CI)=2.47(1.61, 3.79) p<0.0001 Number at risk Pre 674 501 365 247 156 76 Post 676 511 363 246 141 55

  9. Local Recurrence: Pre-op vs Post-op Pre-opSurgery S + RT Survival Meta-analysis 22% 12.5% S + RT 45% S 42% Swedish Trial (25 Gy, 5 tx) 27% 12% S + RT 58% S 48% Dutch (TME) Trial 8.2% 2.4% German 50.4 Gy - 54 6% 76% CR07 25 Gy / 5 tx 5% 72%

  10. Local Recurrence: Pre-op vs Post-op (cont.) Post-opSurgery S + RT Survival Meta-analysis 22.9% 15.3% German Trial (50.4—54.0 Gy, 5 tx) 13% 74% Intergroup 0114 50.4 -- 54 9-13% 53-67% Intergroup 0144 50.4 -- 54 4.6-8% 67-72% CR07 (45 Gy) 17% 61.7%

  11. LR by distance from the anal verge

  12. LR by CRM positivity

  13. LR by TNM Stage

  14. Plane of surgery n=1,119 (83%) • Mesorectal plane 596 53% • Intramesorectal plane 382 34% • Muscularis propria plane 141 13%

  15. LR by CRM and plane Events N 3yr LR 5yr LR CRM -ve Mesorectal plane18 537 3% 8% Intramesorectal plane17 331 7% 8% Muscularis propria plane 11 113 12% 17% CRM +ve Mesorectal plane450 9% 19% Intramesorectal plane5 45 14% 21% Muscularis propria plane 5 27 26% 36%

  16. INT 0114: Total Local Recurrence – 5 Yr. • 14% – Overall (17% at 7 yrs) • 8% – T1,2N+ • 9% – T3N0 • 18% – T3N+ • 24% – T4 any N • RR of 2.1 between low risk (T1,2N+ or T3N0)and high risk (T3N+ or T4 any N) – P < 0.0001

  17. Total mesorectal excision = improvement in circumferential margins • Ability to obtain margins is surgeon dependent • Hospital volume improves results • Ability to obtain margins is stage dependent (Birbeck et al, Ann Surg 2002;235, 449-457)

  18. Risk of local failure vs. margin after TME

  19. Preoperative radiation and mesorectal resection (Dutch Colorectal Cancer Group)

  20. Summary • Local recurrence rate is significantly reduced with pre-op RT compared to post-op RT • Results after post-op chemo/RT are especially poor for Stage III and CRM-positive patients • Study included patients not usually considered for RT • * Stage I (315/1211 pts) • * Upper rectal tumors (204/1322 pts) • - small numbers but LRR is surprisingly high

  21. Summary (cont.) • Distant metastases rate is similar suggesting some impact on survival secondary to LR • Many patients did not receive optimal TME (523/1119 pts) with a significant effect on LR • Additional data: • * Preoperative staging methods • * LR rate by CRM +/- and LN +/- • * Number of LNs sampled

  22. Summary (cont.) • Strategies for evaluation and treatment of rectal cancer: * Define individual patient risk * Staging: ERUS, MRI/CT prior to tx * Recommend pre-op chemo/RT for pts at risk for LR * TME * Quality assurance of radiation, surgery, pathology * Risk of recurrence can continue > 5 years - Surveillance strategies

  23. Questions • Which subsets of pts may not need RT? • Which pre-op RT schedule?: short course v. prolonged course * Define importance of downstaging * Define impact of pCR on survival • Define optimal chemo/RT and adjuvant chemotherapy • * i.e., optimize survival • Monitor acute/chronic toxicities • Tumor biology

  24. Prognostic Significance of Tumor Regression after Preoperative Chemoradiation CAO / ARO / A10-94 Path % pts 5-year DFS % No tumor 10.4 86 > 50% regression 52.2 < 50% regression 13.8 No regression 15.3 63 75 385 pts RT: 50.4 Gy + 5-FU Rodel, JCO 2005; 23:8688-8696

  25. Response No. of Patients % Pathologic response 32* Complete response 8 25 ypT1 0 0 ypT2 6 19 ypT3 18 56 Node negative 23 72 R0 resection 30 94 CALGB 89901: Efficacy NOTE. Clinical T4 at entry, n = 5; pathologic complete response, n = 2. * At phase II dose. 90% CI, 13% to 41%. JCO 2006; 24(16):2557-2565

  26. NSABP R - 04 (October 2005) Randomization Group 1 Group 2 Group 3 Group 4 CVI 5FU CVI 5FU Cape Cape + + Oxali Oxali All patients receive pelvic radiation therapy

  27. E5204 Schema(Postoperative Systemic Therapy) Stage II or III Rectal cancer mFOLFOX6 12 Cycles Randomize mFOLFOX6 + Bevacizumab All patients receive preop chemoradiation n = 2,100

  28. PETACC-6 (EORTC) Capecitabine / RT (45 Gy) TME Capecitabine Capecitabine / Oxaliplatin (50 mg/m²) RT (45 Gy) Capecitabine / Oxaliplatin TME N = 1,100 1° Endpoint = 3-year DFS

More Related